Fluoxetine for Refractory Constipation

NACompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

May 30, 2025

Conditions
Refractory Constipation
Interventions
DRUG

Fluoxetine

Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).

DRUG

Polyethylene Glycol 400 0.4%

The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.

Trial Locations (3)

710032

The First Affiliated Hospital of the Fourth Military Medical University, Xi'an

Xi'an International Medical Center Hospital, Xi'an

750011

People's Hospital of Ningxia Hui Autonomous Region, Yinchuan

All Listed Sponsors
lead

Zhifeng Zhao, PhD

OTHER

NCT06750445 - Fluoxetine for Refractory Constipation | Biotech Hunter | Biotech Hunter